KERX Share Price

Open 6.24 Change Price %
High 6.55 1 Day 0.26 4.18
Low 6.17 1 Week 0.00 0.00
Close 6.48 1 Month -0.36 -5.26
Volume 2334173 1 Year 0.09 1.41
52 Week High 8.38
52 Week Low 4.47
KERX Important Levels
Resistance 2 6.83
Resistance 1 6.69
Pivot 6.40
Support 1 6.27
Support 2 6.13
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX)

KERX Technical Analysis 1.5
As on 31st Oct 2017 KERX Share Price closed @ 6.48 and we RECOMMEND Buy for LONG-TERM with Stoploss of 6.30 & Sell for SHORT-TERM with Stoploss of 6.96 we also expect STOCK to react on Following IMPORTANT LEVELS.
KERX Target for November
1st Target up-side 8.03
2nd Target up-side 9.11
3rd Target up-side 10.2
1st Target down-side 4.93
2nd Target down-side 3.85
3rd Target down-side 2.76
KERX Other Details
Segment EQ
Market Capital 169714688.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.keryx.com
KERX Address
KERX
750 Lexington Avenue
20th Floor
New York, NY 10022
United States
Phone: 212-531-5965
Fax: 212-531-5961
KERX Latest News
Interactive Technical Analysis Chart Keryx Biopharmaceuticals, Inc. ( KERX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Keryx Biopharmaceuticals, Inc.
KERX Business Profile
Keryx Biopharmaceuticals, Inc. (Keryx) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease. The Company is developing KRX-0401, an oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, and also affects a number of other key signal transduction pathways, including the Jun N-terminal kinases pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and survival. KRX-0401 is in Phase III clinical development for both refractory advanced colorectal cancer and relapsed / refractory multiple myeloma, and in Phase I and Phase II clinical development for other tumor types. It is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes.